
Pharmaceutical Executive
Your guide to the world's top 50 pharma companies. The giants may be struggling, but even in a tough year, the industry's most successful companies know how to hit the bullseye.
Pharmaceutical Executive
Your guide to the world's top 50 pharma companies. The giants may be struggling, but even in a tough year, the industry's most successful companies know how to hit the bullseye.
Pharmaceutical Executive
In these cost cutting times, no drugmaker can afford to keep shoveling money down the Rebate Black Hole. Here's how to optimize your ROI and push back against the growing pressure of third-party rebates
Pharmaceutical Executive
Pharmacoactuarial analysis helps drug companies communicate value to health plans
Pharmaceutical Executive
Tracking business by indication is critical for evaluating market performance and making accurate resource allocations
Pharmaceutical Executive
How do you find and license the best drugs out there? If you're Merck, you send scientists to go get 'em
Pharmaceutical Executive
Technology isn't the magic bullet, but it can help you hit your target
Pharmaceutical Executive
The tech-savvy creative team at Concentric Rx has its sales force mixing work and play
Pharmaceutical Executive
Thanks to Dr. Google and Nurse Yahoo, pharma consumers know better than ever how to get exactly what they want
Pharmaceutical Executive
Promotional spending is down as companies rationalize and optimize budgets. But in contrast to big changes on the sales side, marketers are still trying to make the old model work
Pharmaceutical Executive
Meet the Korean pharma consumer: affluent, aging, and crazy about drugs
Pharmaceutical Executive
How to stretch that portfolio to make ends meet
Pharmaceutical Executive
San Diego's booming biotech cluster searches for its future-and yours
Pharmaceutical Executive
FDA is being pressured to get its act together. The agency says it needs more money and more people to get approvals out the door
Pharmaceutical Executive
A plunging currency and other economic turmoil shouldn't phase pharma, right? Yes and no